Skip to content

Clinical randomized controlled study of Lactobacillus mucosus reuteri assisted febuxostadat in the treatment of gout patients with hyperuricemia

Clinical randomized controlled study of Lactobacillus mucosus reuteri assisted febuxostadat in the treatment of gout patients with hyperuricemia

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098798
Enrollment
Unknown
Registered
2025-03-13
Start date
2024-01-20
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gout with hyperuricemia

Interventions

Gout+Febuxostat+probiotics,GFPR:febuxostat: 0.1 mg/tablet orally 2 times daily in the morning and evening for 3 months Lactobacillus reuteri: 0.2g/bag, one sachet at a time, 2 times a day, morning and
Gout+Febuxostat+placebo,GFPL:febuxostat: 0.1 mg/tablet orally 2 times daily in the morning and evening for 3 months Placebo: 0.2g/bag, one sachet at a time, 2 times a day, morning and evening, for 3 m

Sponsors

The Second People's Hospital of Jingdezhen
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Hyperuricemia and Gout (2019) described above. 2. Age>=18 years old, both male and female. 3. Blood uric acid concentration> 420µmol/L. 4. During the treatment period, you can actively cooperate with febuxostat + Lactobacillus reuteri according to the course of treatment. 5. Good spirit, normal cognition, informed consent of patients and their families and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who do not meet the inclusion criteria. 2. Those with serious organ diseases. 3. Those with immune system deficiencies. 4. Have taken uric acid-lowering drugs before inclusion. 5. Those who are allergic to the drugs used in this study. 6. Patients who resist related research work and have poor compliance.

Design outcomes

Primary

MeasureTime frame
gut microbiota;Serum uric acid;Serum creatinine;

Countries

China

Contacts

Public ContactHongying Yu

Jingdezhen Second People's Hospital

yyb89009@qq.com+86 139 7986 2619

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026